TransCode Therapeutics, Inc.
RNAZHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, TransCode Therapeutics, Inc. (RNAZ) is listed under Biotechnology. With a market capitalization of $7.9M, it sits in micro-cap territory. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Market Cap
$7.9M
Beta
1.24
P/E (TTM)
—
P/E (Fwd)
-13.78
EPS (TTM)
$-3.71
EPS (Fwd)
$-0.60
ROE
-52.1%
ROA
-17.1%
Cash
$12.8M
Total Debt
$0
Free CF
-$13.8M
52W Change
-25.5%
Annual Financials
Cash vs Debt
Where RNAZ stands vs its 150-day and 200-day moving averages
As of the July 16, 2026 close, RNAZ finished 7.54% above its 150-day moving average ($8.09) and 1.36% below its 200-day moving average ($8.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RNAZ overbought or oversold?
At the July 16, 2026 close, RNAZ's RSI(14) was 70.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
TransCode Therapeutics, Inc. reports $12.8M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$13.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -52.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for TransCode Therapeutics, Inc. and its sector.